vTv Therapeutics Inc.
For the period ended Nov 6, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 6, 2025 · Filed Nov 6, 2025
VTVT$21.03-3.3%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except per share data)
(in thousands, except per share data)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| (Unaudited) · (Unaudited) | ||||
| Revenue | $— | $— | $— | $1,000 |
| Operating expenses: | ||||
| Research and development | 7,020 | 3,224 | 13,953 | 9,312 |
| General and administrative | 3,679 | 3,282 | 10,970 | 10,976 |
| Total operating expenses | 10,699 | 6,506 | 24,923 | 20,288 |
| Operating loss | (10,699) | (6,506) | (24,923) | (19,288) |
| Interest income | 399 | 504 | 1,005 | 1,136 |
| Interest expense | (5) | — | (5) | — |
| Other (expense)/income, net | (40) | 162 | (19) | (16) |
| Loss before income taxes and noncontrolling interest | (10,345) | (5,840) | (23,942) | (18,168) |
| Income tax provision | — | — | — | 100 |
| Net loss before noncontrolling interest | (10,345) | (5,840) | (23,942) | (18,268) |
| Less: net loss attributable to noncontrolling interest | (1,647) | (1,057) | (4,106) | (3,440) |
| Net loss attributable to vTv Therapeutics Inc. | $(8,698) | $(4,783) | $(19,836) | $(14,828) |
| Net loss attributable to vTv Therapeutics Inc. common shareholders | $(8,698) | $(4,783) | $(19,836) | $(14,828) |
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $(1.08) | $(0.88) | $(2.80) | $(2.70) |
| Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted | 8,055,940 | 5,456,307 | 7,080,681 | 5,498,479 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.